Stocks / Stock overview

Trulieve Cannabis Corp. (TRLV)

$11.10+8.29%Aft $11.03 (-0.63%)Market cap $2.14B

NYSE · Price as of · Delayed Quote

Stock Scorer
Scoring…
Analyst consensus
Strong buy$18.18
  • Analysts7
  • Implied upside+63.8%
  • Target range$15.00 to $21.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
November 5, 2026date estimated
  • EPS expected$0.07
  • A year ago-$0.07
  • Revenue expected$221.9M -23%
  • Estimate range$0.02 to $0.12
Consensus of 2 analysts for the quarter ending September 30, 2026. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
8-KAugust 11, 20268-K
10-QAugust 7, 202610-Q
8-KAugust 7, 20268-K
8-KAugust 5, 20268-K
SCHEDULE 13GJuly 8, 2026View on EDGAR
8-KJuly 2, 20268-K
4June 26, 2026View on EDGAR
4June 25, 2026View on EDGAR
All SEC filings

Frequently asked questions

When does TRLV report earnings?

Trulieve Cannabis Corp. (TRLV) is scheduled to report quarterly results on November 5, 2026 (estimated). The 2-analyst consensus is $0.07 per share on revenue of $221.9M for the quarter ending September 30, 2026, against -$0.07 and $288.2M a year earlier. The date is an estimate from past reporting patterns and can move until the company confirms it.

What do analysts expect for TRLV?

7 analysts cover Trulieve Cannabis Corp. (TRLV). The consensus rating is Strong buy. The average price target is $18.18, in a range of $15.00 to $21.00.

Are insiders buying or selling TRLV?

We have no qualifying Form 4 insider purchases or sales on record for Trulieve Cannabis Corp. (TRLV). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see TRLV SEC filings?

Recent filings are listed on this page, newest first. The latest is an 8-K filed August 11, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.